Compare FTAIN & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
| Metric | FTAIN | HUMAW |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 985 | 184 |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | FTAIN | HUMAW |
|---|---|---|
| Price | $25.38 | $0.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.5K | ★ 14.5K |
| Earning Date | N/A | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.56 | $0.06 |
| 52 Week High | $25.89 | $0.60 |
| Indicator | FTAIN | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 43.88 |
| Support Level | $25.32 | $0.06 |
| Resistance Level | $25.70 | $0.10 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 100.00 | 33.33 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.